Search - tctmd.com

Displaying 761 - 780 of 1300

Sort: Relevancy | Date

Presentation TCT 2013

Prasugrel Preloading in NSTEMI: ACCOAST Recap

Presenter: Gilles Montalescot

October 31, 2013

Presentation TCT 2013

Prasugrel for PCI in ACS and Stable CAD in Japan: PRASFIT-ACS and PRASFIT-Elective

Presenter: Masato Nakamura

October 31, 2013

Presentation TCT 2013

Potential for Rivaroxaban Use in ACS and in the PCI Patient: Why Different Interpretations of the Same Data in the US and Europe?

Presenter: C. Michael Gibson

October 31, 2013

Presentation TCT 2013

Platelet Function Testing is of Clear Clinical Utility in Selected Patients

Presenter: Paul Gurbel

October 31, 2013

Presentation TCT 2013

Platelet Function and Genetic Testing are Currently Worthless

Presenter: Daniel Simon

October 31, 2013

Presentation TCT 2013

OPTIMIZE and ARTIC-INTERRUPTION: Perspectives on DAPT Duration after PCI

Presenter: Peter Wenaweser

October 31, 2013

Presentation TCT 2013

Optimal DAPT Duration Is Not Established: For Now Most Patients Should Stay on DAPT for at Least One Year!

Presenter: Edoardo Camenzind

October 31, 2013

Presentation TCT 2013

New Insights Into High Platelet Reactivity and the Existence of a Therapeutic Window: ADAPT-DES 2-Year Results

Presenter: Ajay Kirtane

October 31, 2013

Presentation TCT 2013

Mortality Trumps All: Ticagrelor for (Nearly) All!

Presenter: Michel Le May

October 31, 2013

Presentation TCT 2013

GIANT: A Prospective Registry Study of CYP2C19 Genetic Profiling for Thienopyridine Management After Primary PCI in Acute Myocardial Infarction

Presenter: Bernard Chevalier

October 31, 2013

Presentation TCT 2013

Genetic Testing is of Clear Clinical Utility in Selected Patients

Presenter: Jessica Mega

October 31, 2013

Presentation TCT 2013

Featured Trial of the Day: OPTIMIZE: A Prospective, Randomized Trial of Three Months vs. 12 Months of Dual Antiplatelet Therapy After PCI

Presenter: Fausto Feres

October 31, 2013

Presentation TCT 2013

Emerging Ticagrelor Data: Insights Into its Safety and Efficacy Profile

Presenter: Dimitrios Alexopoulos

October 31, 2013

Presentation TCT 2013

Dual Anti-Platelet Therapy Plus Warfarin: WOEST Recap, and Recommendations for Adoption

Presenter: Freek Verheugt

October 31, 2013

Presentation TCT 2013

Dual Anti-Platelet Therapy Plus the New Chronic Oral Anticoagulants: What Do We Know?

Presenter: Pascal Vranckx

October 31, 2013

Presentation TCT 2013

Does Dabigatran Increase MI in Patients with Coronary Artery Disease? Addressing the Current Controversy

Presenter: Michael Ezekowitz

October 31, 2013

Presentation TCT 2013

DES Implantation in a Patient with Atrial Fibrillation

Presenter: Roxana Mehran

October 31, 2013

Presentation TCT 2013

Critical Appraisal and Clinical Implications(3)

Presenter: Dean Kereiakes

October 31, 2013

Presentation TCT 2013

Clopidogrel Is Cheap, Effective, and Sufficient for Most!

Presenter: Fausto Feres

October 31, 2013

Presentation TCT 2013

CHAMPION PHOENIX and CHAMPION Program Meta-Analysis

Presenter: Philippe Gabriel Steg

October 31, 2013

Advertisement

Prasugrel Preloading in NSTEMI: ACCOAST Recap

Prasugrel for PCI in ACS and Stable CAD in Japan: PRASFIT-ACS and PRASFIT-Elective

Potential for Rivaroxaban Use in ACS and in the PCI Patient: Why Different Interpretations of the Same Data in the US and Europe?

Platelet Function Testing is of Clear Clinical Utility in Selected Patients

Platelet Function and Genetic Testing are Currently Worthless

OPTIMIZE and ARTIC-INTERRUPTION: Perspectives on DAPT Duration after PCI

Optimal DAPT Duration Is Not Established: For Now Most Patients Should Stay on DAPT for at Least One Year!

New Insights Into High Platelet Reactivity and the Existence of a Therapeutic Window: ADAPT-DES 2-Year Results

Mortality Trumps All: Ticagrelor for (Nearly) All!

GIANT: A Prospective Registry Study of CYP2C19 Genetic Profiling for Thienopyridine Management After Primary PCI in Acute Myocardial Infarction

Genetic Testing is of Clear Clinical Utility in Selected Patients

Featured Trial of the Day: OPTIMIZE: A Prospective, Randomized Trial of Three Months vs. 12 Months of Dual Antiplatelet Therapy After PCI

Emerging Ticagrelor Data: Insights Into its Safety and Efficacy Profile

Dual Anti-Platelet Therapy Plus Warfarin: WOEST Recap, and Recommendations for Adoption

Dual Anti-Platelet Therapy Plus the New Chronic Oral Anticoagulants: What Do We Know?

Does Dabigatran Increase MI in Patients with Coronary Artery Disease? Addressing the Current Controversy

DES Implantation in a Patient with Atrial Fibrillation

Critical Appraisal and Clinical Implications(3)

Clopidogrel Is Cheap, Effective, and Sufficient for Most!

CHAMPION PHOENIX and CHAMPION Program Meta-Analysis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content